Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more
Herantis Pharma Oyj - Asset Resilience Ratio
Herantis Pharma Oyj (HRTIS) has an Asset Resilience Ratio of 89.18% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Herantis Pharma Oyj's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Herantis Pharma Oyj's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €446.00K | 8.72% |
| Short-term Investments | €4.11 Million | 80.46% |
| Total Liquid Assets | €4.56 Million | 89.18% |
Asset Resilience Insights
- Very High Liquidity: Herantis Pharma Oyj maintains exceptional liquid asset reserves at 89.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Herantis Pharma Oyj Industry Peers by Asset Resilience Ratio
Compare Herantis Pharma Oyj's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Herantis Pharma Oyj (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Herantis Pharma Oyj.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 83.02% | €2.13 Million | €2.57 Million | -13.16pp |
| 2023-12-31 | 96.18% | €6.49 Million | €6.75 Million | +0.06pp |
| 2022-12-31 | 96.13% | €5.99 Million | €6.23 Million | +14.98pp |
| 2020-12-31 | 81.15% | €13.32 Million | €16.42 Million | +72.25pp |
| 2019-12-31 | 8.90% | €985.24K | €11.07 Million | -11.62pp |
| 2018-12-31 | 20.52% | €1.47 Million | €7.15 Million | -25.38pp |
| 2017-12-31 | 45.90% | €5.31 Million | €11.57 Million | +25.84pp |
| 2016-12-31 | 20.06% | €2.05 Million | €10.21 Million | -15.43pp |
| 2015-12-31 | 35.49% | €5.00 Million | €14.09 Million | +4.98pp |
| 2014-12-31 | 30.51% | €9.00 Million | €29.49 Million | -- |
| 2012-12-31 | 0.00% | €0.00 | €2.21 Million | -- |